Drug intelligence / Profile preview

CA-1

Development stage: Preclinical
Lead developer: Grann
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CA-1 is an mRNA-based therapeutic candidate being developed by Grann Pharmaceuticals for the treatment of colorectal adenocarcinoma. Currently in the preclinical stage (including both in vitro and in vivo studies), the drug leverages mRNA technology to potentially express therapeutic proteins or antigens within the tumor microenvironment. While the specific molecular target or encoded sequence has not been publicly disclosed, CA-1 is part of Grann's pipeline of advanced nucleic acid therapeutics. The company generally focuses on combining mRNA lipid nanoparticle (LNP) technology with small molecule treatments to address complex diseases.

Other names: CA-1-Grann-mRNA-Colorectal adenocarcinomaCA1-Grann-mRNA-Colorectal adenocarcinomaCA 1-Grann-mRNA-Colorectal adenocarcinoma

Beyond the preview

Go deeper on CA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CA-1.

Explore the full profile